Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2009 Dec;10(12):1315-24.

GM-CSF-secreting vaccines for solid tumors.

Author information

1
The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA. emensle@jhmi.edu

Abstract

Whole tumor cells that secrete GM-CSF have been tested in clinical trials and have demonstrated early evidence of safety and clinical activity. The intradermal administration of these cells induces a massive infiltration of dendritic cells, which process and present tumor antigens to activate tumor-specific CD4+ and CD8+ T-cells. However, trial design flaws limit the phase III evaluation of this vaccine platform. Preclinical and clinical data suggest the development of GM-CSF-secreting tumor vaccines should be continued in combination with drugs that enhance vaccine activity by mitigating immune tolerance or augmenting costimulatory pathways of T-cell activation.

PMID:
19943203
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center